Press Releases Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
208.5 ^TWD	-0.24%		-3.92%	+205.27%

May. 14	Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 14	Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumosa Therapeutics : Board Approved the Revised Exclusive Licensing Agreement for the Veterinary Analgesic	22-08-09	PU
Lumosa Therapeutics : Board Approved the Binding Term Sheet for LT1001, a Long-acting Analgesic Injection, with a Pakistani Pharmaceutical Company	22-08-09	PU
Lumosa Therapeutics : Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards	22-08-09	PU
Lumosa Therapeutics : Board of Directors approved the consolidated financial report for the second quarter of 2022	22-08-09	PU
Lumosa Therapeutics : Partner, AMed Co., Informed the Receipt of Market Authorization from Malaysia NPRA for Naldebain, an Extended-Release Analgesic Injection	22-06-05	PU
Lumosa Therapeutics : Board Approved the Amendments for the Exclusive Licensing Agreement for the Veterinary Analgesic	22-05-31	PU
Lumosa Therapeutics : Shareholders' Meeting approved to release the company's directors from non-competition restrictions	22-05-24	PU
Lumosa Therapeutics : Important resolutions of LUMOSA's 2022 Annual Shareholders' Meeting	22-05-24	PU
Lumosa Therapeutics : Announcement of cancellation of part of new restricted employee shares by relevant authority	22-05-20	PU
Lumosa Therapeutics : Board of Directors not to proceed with the private placement of ordinary shares approved by the 2021 annual general meeting of shareholders	22-04-22	PU
Lumosa Therapeutics : Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards	22-04-22	PU
LUMOSA Therapeutics : announces TFDA’s clearance of Phase 2 IND application for multiple-dose of LT3001 in patients with acute ischemic stroke.	22-03-24	PU
Lumosa Therapeutics : Board of Directors approved the convening of the 2022 Annual shareholders' Meeting	22-03-04	PU
Lumosa Therapeutics : Board of Directors approved to issue common shares via private placement.	22-03-04	PU
Lumosa Therapeutics : Board of Directors approved the 2021 consolidated financial report	22-03-04	PU
Lumosa Therapeutics : Receives the Results of LT1001 Phase 3 Trial Conducted by Chinese Partner, Jemincare	22-02-25	PU
Lumosa Therapeutics : Announcement of cancellation of part of new restricted employee shares by relevant authority	22-02-23	PU
Lumosa Therapeutics : Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke.	22-02-09	PU
Lumosa Therapeutics : Announces the Termination of “Comparative BA Study” for Naldebain, a New Long-Acting Analgesic Injection, in the US Due to Additional USFDA Requirements	22-01-26	PU
Lumosa Therapeutics : Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke	21-08-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

Press Releases

Filters